December 10, 2018

Four years’ experience of EHLs reported

Long-term outcomes of prophylaxis with the extended half-life (EHL) factors efmoroctocog alfa (Elocta) and eftrenonacog alfa (Alprolix) were reported at the 60thAnnual Meeting of the American Hematology Society in San Diego.

The data come from 4-year extension studies: ASPIRE followed on from the A-LONG trials in haemophilia A and B-YOND included patients with haemophilia B who completed the B-LONG trial. Both trials were primarily designed to evaluate the risk of developing inhibitors; neither was randomised or blinded.

The companies say that, in ASPIRE, the median annualised rate remained low and individualised dosing was associated with no spontaneous joint bleeds. Joint health scores improved. The dose interval did not change or increased in 92% of participants. In B-YOND, total joint and spontaneous joint median annualised bleeding rates in adults and young people were <1.58 and <0.38, respectively, and <0.85 and 0 in children <12 years old. The dose interval was unchanged or increased in 85% of adults and 93% of children.